Atrinsic (NASDAQ:PTIX) Trading Up 14.5% – Should You Buy?

Atrinsic Inc. (NASDAQ:PTIXGet Free Report)’s stock price rose 14.5% during mid-day trading on Tuesday . The company traded as high as $0.21 and last traded at $0.21. Approximately 2,574 shares changed hands during mid-day trading, a decline of 92% from the average session volume of 30,919 shares. The stock had previously closed at $0.1834.

Atrinsic Stock Down 15.0%

The firm has a fifty day moving average of $0.34 and a 200-day moving average of $0.48. The firm has a market cap of $398,200.00, a P/E ratio of -0.03 and a beta of 1.07.

Atrinsic Company Profile

(Get Free Report)

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc is headquartered in New York, New York.

Further Reading

Receive News & Ratings for Atrinsic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrinsic and related companies with MarketBeat.com's FREE daily email newsletter.